Highlights of weekly biotech stock moves
Regulatory, clinical and other milestones
Acura Pharmaceuticals Inc. (NASDAQ:ACUR) lost $0.17 (14%) to $1.06 last week after saying FDA advised the company that data from the Phase II Study 301 are "insufficient to support an intranasal abuse deterrence claim" for Acura's Vycavert, an oral, immediate-release formulation of hydrocodone with acetaminophen that uses the company's Aversion abuse-deterrent technology.
Acura previously said it expected to submit an NDA to FDA for the product this half. The company said it will determine a revised timeline following a meeting with FDA. At least one analyst downgraded the stock (see "Analyst Picks" A15).